Rhinostics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rhinostics, Inc. - overview
Established
2020
Location
Boston, MA, US
Primary Industry
Medical Devices & Equipment
About
Based in Massachusetts, US, Rhinostics, Inc. was founded in 2020 by co-founders Michael Springer Ph. D and Richard Novak Ph. D.
The FDA (Food and Drug Administration) has approved the RHINOsticTM product as a Class I exempt medical device. In December 2020, the company raised seed funding, followed by Series A funding in March 2021. Rhinostics' nasal swab collection kits incorporate a one-piece cap-and-swab combination with a barcode on the bottom of the collection vial for automated de-capping and swab removal, as well as simultaneous scanning of several vials. The company generates revenue by offering a system that allows for sample collection, quick accessioning, and automated cap removal, which can be coupled to high throughput Covid-19 tests from laboratory operations.
Current Investors
Avestria Ventures, Covid Apollo Project, Shadow Ventures
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.rhinostics.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Rhinostics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.